NCT00410046

Extension Study Evaluating Etanercept in Ankylosing Spondylitis

An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to evaluate the health care resource utilization and work status of patients with ankylosing spondylitis undergoing treatment with etanercept by comparing study evaluations with the baseline evaluations in the ASCEND (0881A3-402)(NCT00247962) study.

Conditions

• Ankylosing Spondylitis

Interventions

Type	Name	Description
DRUG	Enbrel (etanercept)	Etanercept 50 mg SC injection once weekly

Timeline

• Start date: 2006-12-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2006-12-12
• Last updated: 2012-05-11
• Results posted: 2012-05-11

Locations

16 sites across 4 countries: Denmark, Finland, Sweden, United Kingdom